Sam Altman at the White House on Jan. 21 (Andrew Harnik/Getty Images)
January 24, 2025 03:24 PM EST
Financing
Startups

With Sam Alt­man’s help, Retro Bio­sciences eyes $1B to ex­tend lifes­pan by 10 years

Kyle LaHucik

Senior Reporter

Dis­ease-re­ver­sal start­up Retro Bio­sciences is aim­ing for a $1 bil­lion fund­ing round, a spokesper­son for the com­pa­ny con­firmed in a Fri­day email to End­points News …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­com­ing PDU­FA dates may be en­snared by Trump's pause at HHS, an­a­lyst says

Mer­ck and Ei­sai re­veal late-stage fail for Keytru­da and Lenvi­ma in gas­troe­sophageal can­cer

Mod­er­na in­for­ma­tion chief to re­tire next month; Pharm­ing looks to Flag­ship for first new CEO since 2008

No­vo Nordisk’s amy­cretin prompts 22% weight loss in ear­ly obe­si­ty tri­al

Take­da dis­con­tin­ues US sup­ply of gout drug Uloric over gener­ic com­pe­ti­tion 

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times